Tocopherol Emulsions as Functional Autoantigen Delivery Vehicles Evoke Therapeutic Efficacy in Experimental Autoimmune Encephalomyelitis.
Animals
Autoantigens
/ administration & dosage
Cytokines
/ metabolism
Emulsions
/ chemistry
Encephalomyelitis, Autoimmune, Experimental
/ drug therapy
Female
Immune Tolerance
/ drug effects
Immunotherapy
/ methods
Mice
Mycobacterium tuberculosis
/ drug effects
Spleen
/ cytology
Tocopherols
/ chemistry
antigen-specific immunotherapy
antioxidant
codelivery
experimental autoimmune encephalomyelitis (EAE)
proteolipid protein (PLP139−151)
tocopherol
Journal
Molecular pharmaceutics
ISSN: 1543-8392
Titre abrégé: Mol Pharm
Pays: United States
ID NLM: 101197791
Informations de publication
Date de publication:
04 02 2019
04 02 2019
Historique:
pubmed:
8
1
2019
medline:
19
11
2019
entrez:
8
1
2019
Statut:
ppublish
Résumé
Contemporary approaches to treating autoimmune diseases like multiple sclerosis broadly modulate the immune system and leave patients susceptible to severe adverse effects. Antigen-specific immunotherapies (ASIT) offer a unique opportunity to selectively suppress autoreactive cell populations but have suffered from marginal efficacy even when employing traditional adjuvants to improve delivery. The development of immunologically active antigen delivery vehicles could potentially increase the clinical success of antigen-specific immunotherapies. An emulsion of the antioxidant tocopherol delivering an epitope of proteolipid protein autoantigen (PLP
Identifiants
pubmed: 30615457
doi: 10.1021/acs.molpharmaceut.8b00887
pmc: PMC6557722
mid: NIHMS1023551
doi:
Substances chimiques
Autoantigens
0
Cytokines
0
Emulsions
0
Tocopherols
R0ZB2556P8
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
607-617Subventions
Organisme : NIGMS NIH HHS
ID : P20 GM103638
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM008359
Pays : United States
Références
J Control Release. 2003 Jan 9;86(1):33-48
pubmed: 12490371
Nature. 1998 Mar 19;392(6673):245-52
pubmed: 9521319
J Neuroimmune Pharmacol. 2015 Dec;10(4):528-46
pubmed: 25946987
J Exp Med. 2000 Feb 7;191(3):411-6
pubmed: 10662786
Scientifica (Cairo). 2013;2013:249101
pubmed: 24278770
Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):E156-65
pubmed: 25548186
Mol Immunol. 1991 Mar;28(3):279-84
pubmed: 1850114
Methods Mol Biol. 2017;1494:165-180
pubmed: 27718193
Int J Pharm. 2005 Jul 25;298(2):315-22
pubmed: 15961266
J Pharm Sci. 2010 Aug;99(8):3552-60
pubmed: 20564384
Mol Ther Methods Clin Dev. 2014 Apr 09;1:14008
pubmed: 26015953
Biomaterials. 2010 May;31(13):3657-66
pubmed: 20138662
Eur J Immunol. 2004 Dec;34(12):3572-81
pubmed: 15549728
J Neuroimmunol. 2004 May;150(1-2):59-69
pubmed: 15081249
Clin Exp Immunol. 2010 Oct;162(1):1-11
pubmed: 20682002
Anal Biochem. 1996 Jul 15;239(1):70-6
pubmed: 8660627
Sci Rep. 2016 Sep 22;6:33808
pubmed: 27654170
Blood. 1994 Jan 1;83(1):113-8
pubmed: 8274730
Anal Chem. 2010 Mar 1;82(5):1608-11
pubmed: 20143890
Adv Mater. 2012 Jul 24;24(28):3724-46
pubmed: 22641380
Eur J Pharm Sci. 2013 May 13;49(2):175-86
pubmed: 23485439
Lab Invest. 1990 Oct;63(4):476-89
pubmed: 1700193
Methods Mol Biol. 2012;900:381-401
pubmed: 22933080
J Pharm Sci. 2015 Feb;104(2):346-61
pubmed: 25447598
Neurol Sci. 2009 Oct;30 Suppl 2:S159-62
pubmed: 19882366
Clin Exp Immunol. 2014 Mar;175(3):397-407
pubmed: 24102425
Nat Immunol. 2007 Dec;8(12):1390-7
pubmed: 17994024
Nat Mater. 2013 Nov;12(11):978-90
pubmed: 24150416
J Neuroimmune Pharmacol. 2013 Dec;8(5):1251-64
pubmed: 23821341
Cell Rep. 2016 Sep 13;16(11):2940-2952
pubmed: 27626664
J Immunol. 1998 Oct 1;161(7):3299-306
pubmed: 9759845
Int Immunol. 1997 Sep;9(9):1243-51
pubmed: 9310827
Biomaterials. 2011 Jun;32(16):4058-66
pubmed: 21396707
J Immunol. 2006 Jul 1;177(1):566-73
pubmed: 16785554
AAPS J. 2014 Nov;16(6):1204-13
pubmed: 25297853
Anal Bioanal Chem. 2017 Jul;409(19):4529-4538
pubmed: 28555342
J Control Release. 2017 Nov 28;266:156-165
pubmed: 28963036
NeuroRx. 2005 Jan;2(1):3-14
pubmed: 15717053
Curr Opin Microbiol. 2010 Feb;13(1):106-12
pubmed: 20079678
Ther Adv Neurol Disord. 2015 Jan;8(1):31-45
pubmed: 25584072
J Immunol. 1991 Dec 1;147(11):3815-22
pubmed: 1940369
Lancet Neurol. 2010 Apr;9(4):438-46
pubmed: 20298967
Nat Rev Immunol. 2015 Apr;15(4):203-16
pubmed: 25720354
Adv Drug Deliv Rev. 2016 Mar 1;98:86-98
pubmed: 26546466
Indian J Med Res. 2013 Nov;138(5):779-95
pubmed: 24434331
Results Probl Cell Differ. 2010;51:43-74
pubmed: 19513635
Proc Natl Acad Sci U S A. 2012 Jul 10;109(28):11270-5
pubmed: 22745170
Can J Neurol Sci. 2004 Feb;31(1):58-63
pubmed: 15038472
Cell Immunol. 2016 Mar;301:74-81
pubmed: 26687613
Eur J Immunol. 2010 Jul;40(7):1830-5
pubmed: 20583029
Pharm Res. 2014 Oct;31(10):2563-82
pubmed: 24848341
Biomacromolecules. 2017 Jun 12;18(6):1893-1907
pubmed: 28474886
Mol Cell Neurosci. 2013 Mar;53:6-13
pubmed: 22771835
Am J Clin Dermatol. 2004;5(5):357-9
pubmed: 15554737
Eur J Immunol. 2008 May;38(5):1404-13
pubmed: 18389478
Int J Clin Pract. 2010 Apr;64(5):637-50
pubmed: 20456216
Lancet. 2017 Apr 1;389(10076):1347-1356
pubmed: 27889192
Curr Pharm Biotechnol. 2014;15(3):276-96
pubmed: 24938888
Trends Biotechnol. 2018 Jul;36(7):686-699
pubmed: 29588069